PMID- 30506426
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20200511
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Print)
IS  - 1355-008X (Linking)
VI  - 64
IP  - 2
DP  - 2019 May
TI  - Therapy of moderate-to-severe Graves' orbitopathy with intravenous 
      methylprednisolone pulses is not associated with loss of bone mineral density.
PG  - 308-315
LID - 10.1007/s12020-018-1823-x [doi]
AB  - PURPOSE: To evaluate the influence of intravenous methylprednisolone (IVMP) pulse 
      administration on bone mineral density (BMD) of the lumbar spine and the femoral 
      neck in patients with moderate-to-severe Graves' orbitopathy (GO). METHODS: 
      Thirty-five patients with GO in euthyreosis were treated with 12 IVMP pulses 
      (6 x 0.5 g, 6 x 0.25 g on a weekly schedule). Supplementation with 1.0 g of 
      calcium and 800 IU of vitamin D was initiated in all patients before beginning 
      therapy. BMD of the lumbar spine (L1-L4) and the femoral neck were assessed at 
      baseline and after the last IVMP pulse using dual-energy X-ray absorptiometry. To 
      determine differences in BMD between values at baseline and after treatment, we 
      used the least significant change (LSC) methodology. LSC values were calculated 
      to be 3 and 5% for the lumbar spine and the femoral neck, respectively. Change in 
      BMD equal to or exceeding the LSC was assessed as either increase or decrease of 
      BMD. We then compared pre-treatment and post-treatment mean BMD values at the 
      lumbar spine and the femoral neck. RESULTS: We did not observe a decrease of BMD 
      at any site equal to or exceeding the LSC. We found an increase of BMD in at 
      least one measurement site equal to or exceeding the LSC value in 43% of 
      patients, mostly in the lumbar spine (31%). Mean femoral neck BMD did not change 
      while mean lumbar BMD increased. CONCLUSIONS: IVMP given in weekly intravenous 
      pulses does not lead to loss of BMD of the lumbar spine and the femoral neck.
FAU - Rymuza, Joanna
AU  - Rymuza J
AD  - Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 
      Banacha 1a, 02-097, Warsaw, Poland.
FAU - Popow, Michal
AU  - Popow M
AD  - Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 
      Banacha 1a, 02-097, Warsaw, Poland.
FAU - Zurecka, Zuzanna
AU  - Zurecka Z
AD  - Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 
      Banacha 1a, 02-097, Warsaw, Poland.
FAU - Przedlacki, Jerzy
AU  - Przedlacki J
AD  - Department of Nephrology, Dialysis and Internal Medicine, Medical University of 
      Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
FAU - Bednarczuk, Tomasz
AU  - Bednarczuk T
AD  - Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 
      Banacha 1a, 02-097, Warsaw, Poland.
FAU - Miskiewicz, Piotr
AU  - Miskiewicz P
AD  - Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 
      Banacha 1a, 02-097, Warsaw, Poland. piotr.miskiewicz@wum.edu.pl.
LA  - eng
PT  - Journal Article
DEP - 20181201
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Glucocorticoids)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Adult
MH  - Aged
MH  - Bone Density/*drug effects
MH  - Femur Neck/diagnostic imaging/drug effects
MH  - Glucocorticoids/administration & dosage/*adverse effects/therapeutic use
MH  - Graves Ophthalmopathy/*drug therapy
MH  - Humans
MH  - Lumbar Vertebrae/diagnostic imaging/drug effects
MH  - Methylprednisolone/administration & dosage/*adverse effects/therapeutic use
MH  - Middle Aged
MH  - Osteoporosis/*chemically induced/diagnostic imaging
MH  - Young Adult
PMC - PMC6531386
OTO - NOTNLM
OT  - Bone mineral density
OT  - Graves' ophthalmopathy
OT  - Graves' orbitopathy
OT  - Gucocorticoid-induced Osteoporosis
OT  - Methylprednisolone
OT  - Trabecular bone score
COIS- The authors declare that they have no conflict of interest.
EDAT- 2018/12/07 06:00
MHDA- 2020/05/12 06:00
PMCR- 2018/12/01
CRDT- 2018/12/04 06:00
PHST- 2018/08/14 00:00 [received]
PHST- 2018/11/21 00:00 [accepted]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
PHST- 2018/12/01 00:00 [pmc-release]
AID - 10.1007/s12020-018-1823-x [pii]
AID - 1823 [pii]
AID - 10.1007/s12020-018-1823-x [doi]
PST - ppublish
SO  - Endocrine. 2019 May;64(2):308-315. doi: 10.1007/s12020-018-1823-x. Epub 2018 Dec 
      1.